- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04197726
Glycaemic Response to High REsistant STarch Bread (REST)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
In an attempt to increase dietary fibre intake, research has focused on developing wheat-based food products with novel fibres and starches to complement fibre intake from whole grain foods. Resistant starch is starch that escapes digestion in the small intestine and may be fermented in the large intestine by the microbiota. Resistant starch is a type of dietary fibre and it is normally found in wheat-based foods made from refined flour but only in small amounts. White bread made from sbeIIa/b wheat, which has high levels of resistant starch (a type of fibre), is showing promise in modulating blood glucose response and increasing satiety compared with conventional white bread.
The primary aim of this study is to determine whether consumption of sbeIIa/b white bread at breakfast, gives rise to a lower postprandial blood glucose response compared with consumption of a reference white bread in healthy individuals.
Additional aims of the study include: determining whether consumption of sbeIIa/b white bread by healthy subjects, gives rise to a lower glucose concentration in interstitial fluid, as measured by a Continuous Glucose Monitoring system (CGM), compared with consumption of control white bread; and exploring satiety and energy intake changes in healthy individuals following consumption of sbeIIa/b white bread at breakfast, compared with consumption of control white bread.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Norfolk
-
Norwich, Norfolk, Reino Unido, NR4 7UQ
- Quadram Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men and women
- Aged 18 to 65 years
- BMI between 18-25 kg/m2
- Non-smokers
- Those that live within a 40-mile radius of Norwich
Exclusion Criteria:
- Fasting glucose >6.1 mmol/L and/or HbA1c>42 mmol/mol, as assessed by a fasting blood test
- Eligibility screening results indicate they are not suitable to take part in this study
- Smokers (if they have smoked within the 6 weeks prior to the study or during the study)
- Suffer from allergy, intolerance, or sensitivity to gluten, yeast or any of the food ingredients used in this study
- Have a known allergy to adhesives that would prevent proper attachment of the Continuous Glucose Monitoring sensors
- Are pregnant and/or have been pregnant in the last year or are lactating and/or breastfeeding
- Are currently suffering from, or have ever suffered from eating disorders, any diagnosed gastrointestinal disease, gastrointestinal disorders including regular diarrhoea and constipation (excluding hiatus hernia unless symptomatic) or other inflammatory diseases like rheumatoid arthritis (RA), polymyalgia rheumatica or other connective tissues diseases
- Have undergone gastrointestinal surgery; this will be assessed on an individual basis
- Have been diagnosed with diabetes, anaemia as this may affect the study outcome
- Have been diagnosed with any long-term medical condition that may affect the study outcome (e.g. cardiovascular diseases, cancer)
- Regularly take over-the-counter medications for digestive/gastrointestinal conditions
- Use medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including long-term steroids, antibiotics. They may be able to participate if 4 weeks or more have passed from the end of a course such medication
- Regularly take laxatives (once a month or more) as this may affect blood glucose levels
- Take certain dietary supplements or herbal remedies and are unwilling to stop taking them (if required) for two weeks prior to and during the study period
- Are on, or plan to start, a diet programme that may affect the study outcome (e.g. 5:2 fasting diet) unless willing to abstain for 1 month prior to and during the study period
- Went through a weight change of ≥ 3kg in the preceding 2 months
- Have a recent history of substance abuse
- Regularly consume more than 14 units of alcohol a week
- Are unwilling to suspend smoking and vaping for the duration of the study.
- Are participating in another research project that involves dietary intervention or blood sampling.
- Are unwilling to provide GPs contact details
- Are related to or living with any member of the study team.
- Are unable to provide written informed consent
- Have not donated blood or taken part in another dietary intervention in the last 16 weeks and are unwilling to wait until 16 weeks have elapsed
- Those with abnormal blood pressure measurements
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: sbeIIa/b white bread
sbeIIa/b white bread with high resistant starch content
|
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
|
|
Comparador Ativo: Control white bread
Reference white bread (wild-type)
|
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in postprandial capillary glucose concentration
Prazo: 3.5 hours
|
Glucose concentration in capillary blood measured by finger prick test after the consumption of sbeIIa/b white bread compared to control white bread. Measurements will be taken during intervention visit 1 and 2 at -15, -10, -5, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 min. |
3.5 hours
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in postprandial glucose concentration in interstitial fluid
Prazo: 4 hours
|
Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of sbeIIa/b white bread compared to control white bread. Measurements will be taken during intervention visit 1 and 2 between -30 to 210 min. |
4 hours
|
|
Ad libitum intake
Prazo: 2 hours
|
Mean energy intake (kcal) at lunch after consumption of sbeIIa/b and control white bread. Measurements will be taken once during intervention visit 1 and 2. |
2 hours
|
|
Change in postprandial glucose concentration in interstitial fluid
Prazo: 4 hours
|
Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of ad libitum lunch to explore any second meal effects caused by prior intake of either sbeIIa/b white bread and control white bread at breakfast. Measurements will be taken during intervention visit 1 and 2 between 225 to 465 min. |
4 hours
|
|
Satiety
Prazo: 3 hours
|
Change of hunger feeling (appetite) will be examined using visual analog scale (0-10), 0 least and 10 greatest. Measurements will be taken during intervention visit 1 and 2, at 0, 32, 92, 182 min. |
3 hours
|
|
Sensory questionnaire
Prazo: 30 minutes
|
Sensory perception of sbeIIa/b white bread and control white bread will be evaluated using a nine-point hedonic scale to determine any differences overall acceptability based on specific attributes. A Just-About-Right (JAR) scale with five anchor points will be used to measure the appropriateness of the level of specific attributes to evaluate aroma, appearance, taste and texture of breads. Measurements will be taken once during intervention visit 1 and 2. |
30 minutes
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marina Corrado, MSc, PhD student
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- QIB02/2019
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- Protocolo de estudo
- Plano de Análise Estatística (SAP)
- Termo de Consentimento Livre e Esclarecido (TCLE)
- Relatório de Estudo Clínico (CSR)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .